| |
May 1 - 3, 2023 | Jersey City, NJ Don’t miss the opportunity to gain best practices in medical affairs strategy development and ensuring scientific materials are created and shared in a regulatory compliant manner to internal/external stakeholders and thought leaders. Take advantage of the Early Bird Rates, Register Today!
|
|
Today's Big NewsFeb 10, 2023 |
|
Tuesday, February 28, 2023 | 11am ET / 8am PT The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
| By James Waldron Confronted with safety findings, Aristea Therapeutics is not only canning work on its midstage inflammatory program but has decided to dissolve the business entirely. |
|
|
|
By Angus Liu In a tight BCMA CAR-T race, Bristol Myers Squibb has delivered the drug class’s first randomized trial win in multiple myeloma. But the detailed data, recently rejected by the American Society of Hematology for its annual meeting, might simply not matter that much to doctors and the drug’s sales. |
By Andrea Park Two long-standing makers of implants and surgical tools for orthopedic procedures are set to combine into a single musculoskeletal device powerhouse. |
By Max Bayer Blueprint Medicines' momentum has been stymied by a partial FDA clinical hold placed on its solid tumor prospect. The company announced that some patients have experienced visual adverse events, including light sensitivity and blurred vision. |
|
Evidation and Fierce Biotech conducted a survey of industry professionals to gather insights on the role integrated evidence strategies play in their businesses, as well as the impact of these strategies in helping to deliver better health outcomes. Access the findings from this important survey now.
|
|
By Andrea Park Thousands of jobs at Baxter are potentially on the line as the medtech giant embarks on a cost-cutting plan in the wake of a year that CEO José Almeida said had “disappointed” the company. |
By Zoey Becker The Association of the British Pharmaceutical Industry will continue investigating Novo Nordisk, but no longer under the eye of a Novo exec. |
By Andrea Park Titan Medical isn’t quite ready to give up on its robotic surgery technologies—even amid a possible delisting from the Nasdaq, widespread layoffs and a failed attempt at selling off the company. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Zoey Becker,Angus Liu,Fraiser Kansteiner,Eric Sagonowsky,Kevin Dunleavy After New York City's vaccination requirement repeal, the Empire State is rolling bask its mask mandate in hospitals. The CDC has added COVID-19 vaccines to its schedule of regularly recommended shots for kids and adults. Plus more. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we discuss which companies made the list of the top 10 pharma M&A deals of 2022 and what was at stake last year. We also talk about what last year's biggest deal means for M&A activity this year. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now.
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
